TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06470789

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shoulder blood restriction training
Description: Massage massage is also often used to improve the treatment of local body pain, and a large number of studies have shown that massage massage can reduce shoulder pain in the short term, restore shoulder function and improve the range of motion of shoulder joints.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Shoulder blood restriction training
Description: Massage massage is also often used to improve the treatment of local body pain, and a large number of studies have shown that massage massage can reduce shoulder pain in the short term, restore shoulder function and improve the range of motion of shoulder joints.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shoulder blood restriction training
Description: Massage massage is also often used to improve the treatment of local body pain, and a large number of studies have shown that massage massage can reduce shoulder pain in the short term, restore shoulder function and improve the range of motion of shoulder joints.
Study: NCT05810831

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Massage with post isometric relaxation exercises
Description: Post isometric relaxation will be performed in supine position with neutrally positioned head.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Massage
Description: conservative physiotherapy protocol including massage
Study: NCT05189613

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mepolizumab
Description: Subcutaneous Mepolizumab (100 mcg) injection in patients with severe eosinophilic asthma

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: Subcutaneous Mepolizumab (100 mcg) injection in patients with severe eosinophilic asthma
Study: NCT05812040

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Magnetic Resonance Ductography (MRD); and High-Resolution Magnetic Resonance Ductography (HR-MRD)
Description: all participants will receive Magnetic Resonance Ductography (MRD) and High-Resolution Magnetic Resonance Ductography (HR-MRD) examination, using breast dedicated coil and microscopic coil, respectively
Study: NCT04713202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telotristat ethyl
Description: Telotristat Ethyl, 250mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Peptide Receptor Radionuclide Therapy
Description: Peptide Receptor Radionuclide Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peptide Receptor Radionuclide Therapy
Description: Peptide Receptor Radionuclide Therapy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05834309

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: The intervention protocol consists of a 10-minute warm-up doing joint mobility exercises and adaptation exercises to the core exercises of the training session. The exercises will be performed at low intensity in the warm-up. During the main part of the training session, exercises will be performed on a stationary bike at a higher intensity than in the warm-up and strengthening exercises using weights and body weight exercises such as jumping jacks and squats will also be performed. All movements will be performed at 100% of the maximum speed reached in the propulsive phase (understood as executing the movement as fast as possible according to your muscular and functional capacity). The rests between sets will be between 1 and 2 minutes. At the end of the session, there will be a 5-minute return to calm by stretching.
Study: NCT06188169

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Increasing the inspiratory pressure if atelectasis detected by US
Description: The study used US to detect presence of lung atelectasis under mechanical ventilation in pediatrics. Inspiratory pressure increased gradually with continuous monitoring by lung US to minimize the atelectasis as possible.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Increasing the inspiratory pressure if atelectasis detected by US
Description: The study used US to detect presence of lung atelectasis under mechanical ventilation in pediatrics. Inspiratory pressure increased gradually with continuous monitoring by lung US to minimize the atelectasis as possible.
Study: NCT05573659

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: time of cutaneous recoloration
Description: In the shortest time possible (less than 3 minutes), realization of three successive measurements of the time of cutaneous recoloration by a pressure by the so-called visual method by two intensivists trained at the CRT of the surgical resuscitation service familiar with the technique of time of cutaneous recoloration. The measurements will be carried out blindly from each other.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video assisted cutaneous recoloration
Description: Compression of the nail bed of the index of the subject studied until whitening of the pressed area, then release, the force will be equivalent to 300 g on a kitchen scale TPA 808S Techwood™ and time of compressions being of 5 seconds. Smartphone camera recording of the procedure (Iphone 7™, Apple Inc., Cupertino, CA). An assistant is in charge of timing the TRC between two tops given by the operator, the tops corresponding to the release of the pressure on the index so the beginning of the TRC and the total recoloration of the bleached area. This wizard records the three results in seconds with the associated tenth of a second.
Study: NCT05093322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib in combination with Gemcitabine
Description: Surufatinib in combination with Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib in combination with Gemcitabine
Description: Surufatinib in combination with Gemcitabine
Study: NCT05198479

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 77 Lu-DOTA0-Tyr3-Octreotate
Description: Treatment will consist of a cumulative dose of 23.68 - 29.6 GBq (640 - 800 mCi) 177Lu-DOTA0 -Tyr3-Octreotate; Four administrations of 5.92 - 7.4 GBq (160 - 200 mCi) 177Lu-DOTA0-Tyr3-Octreotate; Concomitant amino acids will be given with each administration for kidney protection; 177Lu-DOTA0-Tyr3-Octreotate will be administered at 8±1-week intervals, which can be extended up to 16 weeks to accommodate resolving acute toxicity.
Study: NCT05960071

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: protective lung strategy with recruitment manoeuvre (RM) - steady PEEP
Description: protective lung strategy with recruitment manoeuvre (RM) every 30 minutes and steady PEEP (10) cm H2o in between RM till end of surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: protective lung strategy with recruitment manoeuvre (RM) - decreasing PEEP
Description: protective lung strategy with recruitment manoeuvre (RM) every 30 minutes and decreasing PEEP (15, 10, and 5) cm H20 (10 minutes for each level) in between RM till end of surgery.
Study: NCT06467617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab plus albumin-bound paclitaxel, carboplatin and recaticimab
Description: Adebrelimab (1200 mg,IV, D1, Q3W) +~albumin-bound paclitaxel (260 mg/m2, IV, divided by D1,8,Q3W) +~carboplatin (AUC 5mg/mL/min, IV, D1,Q3W) +~recaticimab (150 mg, SC, D1,Q3W)~21-day cycle
Study: NCT05791383

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous auricular neurostimulation
Description: All transcutaneous auricular neurostimulation procedures will be conducted using the Spark Biomedical device. We will use stimulation parameters similar to ongoing taVNS work (25Hz, 500us pulse width) and a duty cycle of 1 minute on, 30 s off, repeated for 30 minutes. taVNS sessions are considered complete after 30minutes. Subsequent taVNS sessions may be repeated no less than 30minutes after prior session completion. All subjects will begin with taVNS administered to the left auricle, however, if they begin to experience any irritation or discomfort of the left ear, study team staff will offer subjects the option to stop stimulation or switch stimulation to the right auricle.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous auricular neurostimulation
Description: All transcutaneous auricular neurostimulation procedures will be conducted using the Spark Biomedical device. We will use stimulation parameters similar to ongoing taVNS work (25Hz, 500us pulse width) and a duty cycle of 1 minute on, 30 s off, repeated for 30 minutes. taVNS sessions are considered complete after 30minutes. Subsequent taVNS sessions may be repeated no less than 30minutes after prior session completion. All subjects will begin with taVNS administered to the left auricle, however, if they begin to experience any irritation or discomfort of the left ear, study team staff will offer subjects the option to stop stimulation or switch stimulation to the right auricle.
Study: NCT05613166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus will be administrated orally based on seizure events, with an administration interval longer than 24 hours. Participates with a body surface area (BSA) of \<= 1.2 m\^2, the dosage was 2.5 mg/time; for BSA 1.3-2.1 m\^2, the dosage was 5 mg/time; and for BSA \>=2.2 m\^2, the dosage was 7.5 mg/time.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus will be administrated orally based on seizure events, with an administration interval longer than 24 hours. Participates with a body surface area (BSA) of \<= 1.2 m\^2, the dosage was 2.5 mg/time; for BSA 1.3-2.1 m\^2, the dosage was 5 mg/time; and for BSA \>=2.2 m\^2, the dosage was 7.5 mg/time.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Vitamin C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Vitamin C

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vitamin C
Study: NCT05560581

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital self-efficacy training
Description: Prior to the app participation, participants will receive psychoeducation on self-efficacy and will be instructed to define two autobiographical self-efficacy memories (own achievements, e.g., completion of an exam, success in a sporting event). During the week of app participation, they will be prompted three times per day and asked to perform an imagination task. Step by step, they will recall one of their autobiographic self-efficacy memories and focus on their character traits and abilities that were relevant for their achievement.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ecological Momentary Assessment
Description: Participants will receive questions on mood and social/virtual contacts 3 times per day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ecological Momentary Assessment
Description: Participants will receive questions on mood and social/virtual contacts 3 times per day.
Study: NCT05472961

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Target and Stimulus
Description: The investigators manipulate the difficulty of search for the target object by manipulating the number of distractor objects and/or the similarity between the target and distractors. The investigators manipulate the difficulty of the decision about a feature by manipulating the similarity of the feature to a criterion. The investigators manipulate the timing of when the decision feature appears on the object relative to the onset of the array and/or the onset of the saccade away from fixation in a gaze-contingent manner.
Study: NCT05259579

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anti-reflux mucosal ablation
Description: Mucosal ablation is planned around the cardia on the gastric side in a butterfly shape. Submucosal layer is raised by injecting saline with indigo carmine dye. Mucosal ablation is performed using the triangle-tip knife in spray coagulation mode.
Study: NCT05378854

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LifeChamps Platform
Description: Participants will be provided with the study equipment, i.e., a mobile app, smartwatch, smart scale, location home sensor, a smart plug, and a micro-computer, with which they will need to interact with the devices for three months. Specifically, participants should wear the activity tracker wristband (Fitbit Charge 4) as much as possible. Additionally, participants should use the smart scale to weigh themselves and the mobile app to fill in selected PROMs monthly, while the ambient home sensors (location home senor (LOCS) and smart plug) will be passively collecting information about their everyday living during these three months. Lastly, participants' clinical and demographic data from the local EHRs will be collected.
Study: NCT05218681

Intervention type: OTHER
Group type: OTHER
Intervention: Unit-based Person First Anti-stigma Awareness Rounds
Description: Educational rounds on stigma

Intervention type: OTHER
Group type: OTHER
Intervention: Unit-based Person First Anti-stigma Awareness Rounds
Description: Educational rounds on stigma

Intervention type: OTHER
Group type: OTHER
Intervention: Individual Text-based Messaging
Description: Weekly evidence based messages to reduce SUD stigma
Study: NCT05149703

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mezieres Postural Treatment
Description: Implementation of 12 weeks suitable postures of Mezieres method

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mezieres Postural Treatment
Description: Implementation of 12 weeks suitable postures of Mezieres method
Study: NCT05957354

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active continuous Theta Burst Stimulation
Description: Each patient will receive a combination of stimulation sequences, including a 600-pulse cTBS targeting at the right IFG, followed by a 600-pulse cTBS targeting at the right STG, which will be repeated once more (a total of 2400 pulses daily). Each patient will receive a 3-week treatment period, consisting of 5 consecutive workdays each week.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham continuous Theta Burst Stimulation
Description: Each patient will receive a combination of stimulation sequences, including a 600-pulse sham cTBS targeting at the right IFG, followed by a 600-pulse sham cTBS targeting at the right STG, which will be repeated once more (a total of 2400 pulses daily). Each patient will receive a 3-week treatment period, consisting of 5 consecutive workdays each week.
Study: NCT04999540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucidinostat
Description: 30 mg, administered orally twice per week (BIW)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant was supplied as a castor oil based solution in clear neutral glass pre-filled syringes. Each syringe will contain 250 mg of fulvestrant in 5 ml.
Study: NCT05521308

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing Aid - Standard Curve
Description: Our current hearing aids which will be programmed to our standard frequency response curve.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing Aid - Variation #1
Description: Hearing aids that will have the frequency response curve adjusted and fit to the participant's hearing loss.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing Aid - Variation #2
Description: Hearing aids that will have the frequency response curve adjusted and fit to the participant's hearing loss.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing Aid - Variation #3
Description: Hearing aids that will have the frequency response curve adjusted and fit to the participant's hearing loss.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing Aid - Variation #4
Description: Hearing aids that will have the frequency response curve adjusted and fit to the participant's hearing loss.
Study: NCT05419401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capivasertib film-coated tablet, 200 mg
Description: 400mg dose, oral, fasted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]AZD5363 (Capivasertib)
Description: Solution for Infusion 20 µg/mL (NMT 37.0 kBq/5 mL) - 100 µg; 5 mL, Intravenous~Oral Solution, 400 mg (NMT 4.8 MBq) - 400mg; 100mL, oral, fasted
Study: NCT06442800

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Liver Cancer
Description: Participants will view messages about the risk of liver cancer from alcohol consumption.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Throat and Mouth Cancer
Description: Participants will view messages about the risk of throat and mouth cancer from alcohol consumption.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Colorectal Cancer
Description: Participants will view messages about the risk of colorectal cancer from alcohol consumption.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multiple Cancers
Description: Participants will view messages about the risk of multiple cancers from alcohol consumption.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Liver Disease
Description: Participants will view messages about the risk of liver disease from alcohol consumption.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypertension
Description: Participants will view messages about the risk of hypertension from alcohol consumption.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dementia
Description: Participants will view messages about the risk of dementia from alcohol consumption.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Drinking Guidelines
Description: Participants will view messages about guidelines for alcohol consumption.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Current Warning
Description: Participants will view the current warning that is required on most alcoholic beverage containers sold in the US.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Participants will view neutral messages unrelated to the harms of alcohol consumption.
Study: NCT04796922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: parsaclisib
Description: parsaclisib will be administered once daily at 20 mg for 8 weeks followed by 2.5 mg once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: rituximab will be administered intravenously on select days as per protocol.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: rituximab
Description: rituximab will be administered intravenously on select days as per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: obinutuzumab
Description: obinutuzumab will be administered intravenously on select days as per protocol.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: obinutuzumab
Description: obinutuzumab will be administered intravenously on select days as per protocol.
Study: NCT05338619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: Lazertinib 240mg (3 Tabs as Laclaza Tab 80mg) once daily in oral can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met.
Study: NCT05327621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamiparib
Description: 40 mg bid per os , 28 day cycle, number of cycles: until progression or unacceptable toxicity develops.
Study: NCT05082584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vadadustat
Description: Vadadustat tablet orally once a day for 52 weeks
Study: NCT05017753

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracentesis
Description: Thoracentesis will be performed according to local practice, either at the ward or at the radiology department, in addition to standard-of-care medical treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-care medical treatment
Description: Standard-of-care medical treatment
Study: NCT06049082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KB408 (Nebulization)
Description: Nebulized solution of KB408, a replication-defective HSV-1 vector expressing full length human SERPINA1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KB408 (Nebulization)
Description: Nebulized solution of KB408, a replication-defective HSV-1 vector expressing full length human SERPINA1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KB408 (Nebulization)
Description: Nebulized solution of KB408, a replication-defective HSV-1 vector expressing full length human SERPINA1
Study: NCT05931003

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carotid stenting
Description: In carotid stenting, a long, hollow tube (catheter) is threaded through the arteries to the narrowed carotid artery in the neck. A metal mesh tube (stent) is inserted into the vessel to serve as a scaffold that helps prevent the artery from narrowing again. The catheter and the filter - which catches any debris that may break off during the procedure - are removed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carotid endarterectomy
Description: Carotid endarterectomy is a procedure to treat carotid artery disease. In carotid endarterectomy receive general anesthesia. Surgeon makes an incision along the front of your neck, opens your carotid artery and removes the plaques that are clogging artery. Then, surgeon repairs the artery with stitches or a patch made with a vein or artificial material (patch graft).~Sometimes surgeons may use another technique called eversion carotid endarterectomy. This involves cutting the carotid artery and turning it inside out, then removing the plaque. Surgeon then reattaches the artery.
Study: NCT04897009

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo blood and tissue collection
Study: NCT05933863

Intervention type: DRUG
Intervention: PD-(L)1 antibody immunotherapy
Description: The treatment regimen involved in this study follows guidelines for the first-line treatment of extensive stage SCLC: cisplatin+etoposide or carboplatin+etoposide and PD-(L)1 inhibitor.
Study: NCT05603884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimen
Description: venetoclax combining chidamide and azacitidine (VCA) 28 days per cycle × 2 cycles； 1) chidamide 30mg biw × 2weeks；2) venetoclax 200mg/d × 2 weeks 3) azacitidine 100mg/d d1-7 dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimen 28 days per cycle ×2 cycles；~1）dicitabine 25mg d1-3，2）liposome mitoxantrone 20mg d4，3）cytarabine 10mg/m2 Q12h d1-7 4）G-CSF 300ug d-1 until WBC \> 20×109/L